Bluebird bio, Inc. Bluebird bio, Inc.

Bluebird bio, Inc.

BLUE

Kedudukan dalam Saham #15697
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Harga Saham
$4.97
Disegerakkan terakhir: 2025-06-02
Modal Pasaran
$318.62M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-38.03%
Negara
US
Perdagangan Bluebird bio, Inc. (BLUE)

Kategori

Healthcare
Nisbah P/B bagi Bluebird bio, Inc. (BLUE)
Nisbah P/B pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Bluebird bio, Inc., nisbah P/B semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/B syarikat ialah 0.
Sejarah nisbah P/B untuk Bluebird bio, Inc. dari 2026 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/B untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/B Perbezaan Nisbah P/B Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.251 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 13.2547 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 4.208 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.1824 -
NL